首页
关于我们疫苗与疾控我们的产品研究开发新闻中心员工社区联系我们
 
 
  站点地图 English
  研究开发
研发策略 合作伙伴
乙脑疫苗研究 论文发表
大流行流感疫苗研究 返回首页
SARS灭活疫苗研究
甲肝灭活疫苗
甲乙肝联合疫苗
SARS疫苗
季节性流感疫苗
大流行流感疫苗
 
SARS疫苗

Genome sequence variation analysis of two SARS coronavirus isolates after passage in Vero cell culture

[概述]
SARS coronavirus is an RNA virus whose replicationis error-prone, which provides possibility for escape of host defenses, and even leads to evolution of new viral strains during the passage or the transmission. Lots of variations have been detected among different SARS-CoV strains. And a study on these variations is helpful for development of efficient vaccine. Moreover, the test of nucleic acid characterization and genetic stability of SARS-CoV is important in the research of inactivated vaccine. The whole genome sequences of two SARS coronavirus strains after passage in Vero cell culture were determined and were compared with those of early passages, respectively. Results showed that both SARS coronavirus strains have high genetic stability, although nearly 10 generations were passed. Four nucleotide variations were observed between the second passage and the 11th passage of Sino1 strain for identification of SARS inactivated vaccine. Moreover, only one nucleotide was different between the third passage and the 10th passage of Sino3 strain for SARS inactivated vaccine. Therefore, this study suggested it was possible to develop inactivated vaccine against SARS-CoV in the future.

[关键词]     severe acute respiratory syndrome (SARS), SARS Coronavirus (SARS-CoV), virus, vaccine.



A serological survey on neutralizing antibody titer of SARS convalescent sera

[概述]
A seroepidemiologic study was conducted in North China in 2003 to determine the neutralizing antibody titer of severe acute respiratory syndrome (SARS) convalescent sera. A total of 99 SARS convalescent serum samples were collected from patients from the Inner Mongolia Autonomous Region, Hebei Province , and Beijing 35-180 days after the onset of symptoms. The anti-SARS antibodies were detected by enzyme-linked immunosorbent assay (ELISA), neutralization assay, and Western blot. Eighty-seven serum samples were confirmed to be positive for SARS antibodies. The neutralizing antibody titer of the 87 positive sera was analyzed quantitatively by neutralization assay. The geometric mean titer (GMT) of the 87 convalescent sera was 1:61. The Kolmogorov-Smirnov test showed that the neutralizing antibody titers conform to normal distribution, which suggests that the average anti-SARS antibody level in this study was representative of the convalescent antibody level of the SARS population. This result could be useful for the development and quality control of SARS vaccines.

[发表刊物]    J. Med. Virol. 77:147-150, 2005. © 2005 Wiley-Liss, Inc.

[全文链接]   http://www3.interscience.wiley.com/cgi-bin/abstract/111082963/ABSTRACT




Preparation and characterization of SARS in-house reference antiserum

[概述]
A reference antiserum for SARS is in urgent need in the development of SARS vaccine and other serological test of SARS research. Convalescent serum was collected from clinical confirmed patient. ELISA, Western-blotting and neutralization assay detected specific antibody against SARS coronavirus. This antiserum was prepared as in-house reference antiserum, freeze-dried and sealed in ampoules. The potency of this reference antiserum is defined to be 52.7 U after extensive calibration. Further, collaborative studies for the evaluation of this serum are needed in order to satisfy the requirements for international reference antiserum.

[关键词] SARS; Reference antiserum; Neutralization antibody potency

[发表刊物] Vaccine, Volume 23, Issues 48-49 , 1 December 2005, Pages 5666-5669 

[全文链接]  http://authors.elsevier.com/sd/article/S0264410X05003014

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
 
Copyright ©2008 北京科兴生物制品有限公司 All rights reserved.